Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
The researchers, led by Dale Boger, co-chair of TSRI’s Department of Chemistry, discovered a way to structurally modify vancomycin to make an already-powerful version of the antibiotic even more potent.
“Doctors could use this modified form of vancomycin without fear of resistance emerging,” said Boger, whose team announced the finding today in the journal Proceedings of the National Academy of Sciences.
The original form of vancomycin is an ideal starting place for developing better antibiotics. The antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it. This suggests bacteria already have a hard time overcoming vancomycin’s original “mechanism of action,” which works by disrupting how bacteria form cell walls.
Boger called vancomycin “magical” for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent. “With these modifications, you need less of the drug to have the same effect,” Boger said.
The new study shows that scientists can make a third modification–which interferes with a bacterium’s cell wall in a new way–with promising results. Combined with the previous modifications, this alteration gives vancomycin a 1,000-fold increase in activity, meaning doctors would need to use less of the antibiotic to fight infection.
The discovery makes this version of vancomycin the first antibiotic to have three independent mechanisms of action. “This increases the durability of this antibiotic,” said Boger. “Organisms just can’t simultaneously work to find a way around three independent mechanisms of action. Even if they found a solution to one of those, the organisms would still be killed by the other two.”
Tested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.
The next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But Boger calls this the “easy part” of the project, compared with the challenge of designing the molecule in the first place.
Even if the process isn’t streamlined, Boger believes the new vancomycin’s lifesaving powers make its production valuable. “Antibiotics are total cures for bacterial infections,” said Boger. “Making this molecule is important, even by the current approach, if the failure of antibiotics continues.”
The Latest on: Vancomycin
- FDA approves premixed vancomycin injection from Xellia Pharmaceuticals on February 20, 2019 at 12:17 pm
Xellia Pharmaceuticals announced that the FDA has approved its premixed vancomycin injection in a ready-to-use bag. The injection is indicated in nonpregnant patients aged 1 month or older to treat se... […]
- Mayo Clinic Study Reports 47% Reduction in C.diff Infection Rates Using Pulsed Xenon UV Room Disinfection on February 20, 2019 at 9:29 am
In addition, the facility saw an increase in patient satisfaction scores for environmental cleanliness and a 52% reduction in Vancomycin-resistant enterococci (VRE) infection rates. Based on the signi... […]
- Ready-to-Use, Room Temp Stable, Premixed Vancomycin Injection Gets FDA Approval on February 19, 2019 at 1:14 pm
Xellia announced that the Food and Drug Administration (FDA) has approved its Premixed Vancomycin Injection in a Ready-to-Use bag. Vancomycin Injection Premix is stable at room temperature (up to 25 °... […]
- Xellia Pharmaceuticals Receives US FDA Approval for Premixed Vancomycin Injection on February 19, 2019 at 1:01 am
COPENHAGEN, Denmark & BUFFALO GROVE, IL.--(BUSINESS WIRE)--Feb 19, 2019--Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announced today ... […]
- Measuring vancomycin use by days of therapy underestimates exposure on February 18, 2019 at 5:48 am
Using days of therapy, or DOT, to estimate vancomycin use may underestimate exposure to the antibiotic by around 10% compared with therapeutic drug-monitoring, or TDM, according to findings published ... […]
via Google News and Bing News